• USFDA awards Breakthrough Therapy designation to Novartis’ asciminib pharmaceutical-business-review
    February 10, 2021
    Novartis has announced that the novel investigational treatment asciminib, specifically targeting the ABL myristoyl pocket (STAMP), has been awarded Breakthrough Therapy designation (BTD) by the US Food and Drug Administration (FDA).
PharmaSources Customer Service